Pharmacogenomics (PGx) Clopidogrel CYP2C19 Test
A targeted pharmacogenomic test evaluating CYP2C19 metabolizer status to optimize clopidogrel prescription and dosing, powered by the Helix Exome+® platform.
6-9 days
≤ 5 minutes
Test Description
Clopidogrel is an antiplatelet medication prescribed to patients at increased risk of blood clots, including those who have a history of cardiac events or major cardiac intervention. Clopidogrel prevents the collection of platelets and formation of blood clots in the blood vessels.
This test evaluates a patient’s metabolizer status for CYP2C19, which can aid in appropriate prescription and dosing to reduce risk of side effects and treatment failure with clopidogrel.
Have Questions?
Our team is available Monday through Friday, 9am-5pm Pacific Time.
Indications for Testing
Patients in whom clopidogrel therapy is being considered for cardiovascular or neurovascular indications.
Methodology
This test utilizes next-generation sequencing to determine star alleles and metabolizer status for CYP2C19 and is used to determine drug considerations for Clopidogrel.
Technical Specifications
CYP2C19: *1-*19, *22-*26, *28-*39
Genes Tested
Showing 1 of 1 genes in this panel